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Stem cells are proposed to continuously secrete trophic factors that potentially serve as mediators of autocrine and paracrine
activities, associated with reprogramming of the tumor microenvironment, tissue regeneration, and repair. Hitherto, significant
efforts have been made to understand the level of underlying paracrine activities influenced by stem cell secreted trophic factors,
as little is known about these interactions. Recent findings, however, elucidate this role by reporting the effects of stem cell
derived extracellular vesicles (EVs) that mimic the phenotypes of the cells from which they originate. Exchange of genetic
information utilizing persistent bidirectional communicationmediated by stem cell-EVs could regulate stemness, self-renewal, and
differentiation in stem cells and their subpopulations. This review therefore discusses stem cell-EVs as evolving communication
factors in stem cell biology, focusing on how they regulate cell fates by inducing persistent and prolonged genetic reprogramming
of resident cells in a paracrine fashion. In addition, we address the role of stem cell-secreted vesicles in shaping the tumor
microenvironment and immunomodulation and in their ability to stimulate endogenous repair processes during tissue damage.
Collectively, these functions ensure an enormous potential for future therapies.
1. Introduction
Stem cell technology has recently attracted considerable
attention in translational medicine due to the potential that
these cells possess in terms of tissue regeneration and repair
and as drug delivery tools for which existing therapeutic
strategies pose enduring challenges. In recent years, the fields
of regenerative and translational medicine have proven to
be very attractive owing to the discovery of novel cellular
and noncellular therapeutic platforms for tissue repairs and
cancer treatments.
This reviewmainly engages studies carried out on the two
major types of stem cell lines: embryonic stem cells (ESCs)
and mesenchymal stem cells (MSCs). Nevertheless, several
other types of stem cells closely related to their tissue of origin
(e.g., adipose stem cells, cancer stem cells) have also been
reported.
ESCs are pluripotent cells with the ability to differentiate
into cells from any of the three germ layers: mesoderm,
endoderm, and ectoderm. They have the capability to self-
renew and proliferate limitlessly, but their application in
Hindawi Publishing Corporation
Stem Cells International
Volume 2016, Article ID 1073140, 17 pages
http://dx.doi.org/10.1155/2016/1073140
2 Stem Cells International
research and therapy has been limited due to ethical concerns
on availability and the risk of forming teratomas.
In the last two decades, more attention has been diverted
towards MSCs as they are easily obtainable and show
therapeutic promise. MSCs are a nonhematopoietic, het-
erogeneous population of plastic-adherent cells that exhibit
a fibroblast-like morphology. They form distinct colonies
when seeded at clonal densities, and their heterogeneity
is distinguished through morphological differences, rate of
proliferation, and their ability to differentiate [1]. According
to the current nomenclature, human MSCs can be identified
through their positivity for cell surfacemarkers such asCD73,
CD90, andCD105 and the lack of expression of hematopoietic
markers such as CD11b or CD34, CD45, CD79 or CD19,
and HLA-DR [2]. Furthermore, they must have the ability to
differentiate into osteoblasts, chondrocytes, and adipocytes in
vitro [2]. The biological effects of MSCs depend largely on
their ability to secrete trophic factors that stimulate tissue-
intrinsic progenitor cell phenotypes [3].These factors include
growth factors, miRNAs, and small vesicles that not only
potentially affect the differentiation and regenerative abilities
of MSCs but also play a critical role in mediating crosstalk to
local and distant tissues through which stem cell populations
maintain a stable coexistence [4].
Recent evidence shows that stem cells secrete small
vesicles into the extracellular milieu, known as extracellular
vesicles (EVs). EVs are submicron vesicles, which based on
their size, origin, morphology, and mode of release can be
categorized into exosomes (40–200 nm), microvesicles (50–
1000 nm), apoptotic bodies (50–5000 nm), or Golgi vesicles
(reviewed in [5]). EVs are secreted by a multitude of cell
types into various body fluids [6] and can be isolated via
several conventional as well as high throughput technologies
[5]. They are known to carry a repertoire of mRNAs, miR-
NAs, DNA, proteins, and lipids that can be transferred to
neighboring cells, modifying their phenotype as well as the
microenvironment [7, 8]. The molecular signatures of EVs
are selective to each cell/tissue type, which makes them ideal
source for clinical applications [5].
The biogenesis and secretion of EVs from biologically
active cells are a stimulus dependent event that is arising as
a result of tumor progression or repair processes. A well-
studied process of formation of exosomes is by the fusion
of the multivesicular endosome with plasma membrane and
release by the process of exocytosis. Conversely,microvesicles
are less well characterized in comparison to exosomes and
are produced as a result of membrane budding processes and
detachment of spherical bodies from discriminatory regions
of the plasma membrane (for mechanisms, see [5]). Recently,
Golgi vesicles were highlighted, considering them a part of
the extracellular vesicle populations as separate entities. Like
other vesicles, they may reflect distinct disease states [5],
and their role could be hypothesized for underappreciated
effectors in stem cell context.
Interestingly, it has been shown recently that MSC exo-
somes are derived from endocytosed lipid-raftmicrodomains
[9]. Arguably, the knowledge about the mechanisms of
biogenesis and origin of EVpopulations from stem cells could
enhance our understanding of the functional relevance and
help acquire therapeutic possibilities using stem cell-EVs.
2. Intercellular Communication and Transfer
of Biological Information
Cells use severalmeans of communication for the exchange of
materials and the transfer of information in order tomaintain
tissue homeostasis, cell development, repair, and survival.
Intercellular communication is therefore considered one of
the most important regulatory mechanisms for cell growth,
differentiation, and tissue remodeling. This intercellular
crosstalk may occur through direct receptor-mediated inter-
action between cells, or through cellular junctions (i.e., cell
fusion). Certainmolecules, specific transmembrane proteins,
and cell adhesion molecules such as integrins, tetraspanins,
and cadherins are known to promote receptor-mediated
cellular interactions that are critical in the formation of
biological patterns as well as determining cell fates [10, 11].
On the other hand, the direct coupling of the cytoplasm of
two cells through gap junctions (GJs) has also been reported
to play an essential role in maintaining tissue homeostasis,
development, and stem cell differentiation [12, 13].
It has been proposed that normal human adult stem
cells do not express gap junctional proteins (i.e., connexins)
and do not appear to have gap junctional intercellular
communication. However, their differentiated, nonstem cell
derivatives do express connexins and therefore utilize GJs
for intercellular communication in order to differentiate [14].
Remarkably, bone marrow derivedMSCs have been reported
to differentiate into cells with a cardiac phenotype in response
to signals from neighboring myocytes, as a result of gap
junctional intercellular communication [15]. Arguably, the
crucial role that these interactions play in the maintenance
of tissue integrity in a plethora of different cell types such as
endothelial cells, fibroblasts, adipocytes, cardiomyocytes, and
neurons is of critical translational importance.
2.1. Tunneling Nanotubes and Intercellular Communication.
Recently, a novel mechanism for cellular communication
involving long distance intercellular connections called tun-
neling nanotubes (TNTs) has come to light [16]. TNTs are
actin-based cytoplasmic extensions that not only facilitate
direct communication between distant cells and intercellular
trafficking [17] but also are associated with the transfer of
biomolecular cargos such as organelles, Golgi vesicles, plasma
membrane components, and even pathogens [18–20]. These
functions of TNTs have therefore implicated them in the
promotion of various physiological (tissue development and
regeneration [21]) as well as pathological processes such as
mesothelioma [22].
For instance, extensive spontaneous intercellular
exchange of cytosolic materials and organelles, between
primary human proximal tubular epithelial cells, was recently
reported [23]. Interestingly, this exchange was alleviated
significantly on inhibiting TNT genesis, therefore implying
the importance of TNTs in renal physiology [23].
Surprisingly, the direct transfer of genetic material between
tumor and stromal cells has also been identified to be
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mediated through TNTs, exclusive of other forms of cell-cell
communication, therefore suggesting a role of TNTs in
tissue remodeling as well [24]. A recent study described the
nanotubular connections and tubule fragments in multi-
potent MSCs from human arteries, demonstrating that
they interact constitutively through an articulate and dyn-
amic tubule network allowing long-range cell-to-cell com-
munication [25].This therefore suggests that one mechanism
by which MSCs exhibit their protective effects on the heart
may be through tubular communication.
2.2. Cell-Cell Communication through Paracrine Secreted
Factors. Diffusion of autocrine and paracrine signaling
molecules enables cells to communicate in the absence of
physical contact. The beneficial effects of stem cells are
therefore restricted not only to cell-to-cell contact alone, but
also to their transient paracrine actions through the release
of a combination of trophic factors including cytokines,
chemokines, and growth factors [26–28]. These factors have
been shown to have various functional properties such as
being antiapoptotic, immunomodulatory, and angiogenic,
playing a role in cell-mobilization, evoking responses from
resident cells in the extracellular environment, and facilitat-
ing collateral remodeling [29]. Through receptor-mediated
interactions, these paracrine mechanisms potentially facili-
tate the homing of stem cells to sites of tissue injury, therefore
allowing recipient cells to interact with stem cell factors
that may influence the regulation of differentiation and anti-
inflammatory responses [26].
Cells could also communicate through secreted extra-
cellular RNAs, which, once transferred from one cell to
another, may modulate the phenotype and function of the
recipient cells. Furthermore, the exchange of extracellular
RNAs between resident cells and MSCs has been implicated
in the modulation of cell fate [30]. These extracellular RNAs
are secreted, vesicle-encapsulated or in association with
proteins that confer protection from degrading enzymes and
contribute towards the microenvironmental modulation of
cell fate with other extracellular factors such as the extracel-
lular matrix as well as the local biochemical and mechanical
niches [31].
2.3. Extracellular Vesicles as Novel Means of Communication.
Secreted EVs exhibit novel paracrine mechanisms mediating
cell-to-cell communication through receptor-ligand medi-
ated interactions and/or direct fusion with resident cells,
resulting in the horizontal transfer of various proteins as well
as genetic material (including mRNA [8, 32–34] and miRNA
[34]). As paracrine factors, EVs have been reported to induce
phenotypic changes in recipient cells and also generate a
functional link between stem cells and tissues under various
physiological and pathological circumstances (reviewed in
[33]).
Recently, it has been demonstrated that EVs released by
human adipocytes or adipose tissue-explants are involved
in a reciprocal proinflammatory loop between adipocytes
and macrophages in a paracrine fashion, with the possi-
bility to aggravate insulin resistance locally or systemically
[35]. Moreover, EVs released from osteoblasts serve as
a mechanism of communication between osteoblasts and
osteoclasts through receptor-ligand interactions to facilitate
osteoclast formation that represent a novel mechanism of
bone remodeling [36].
Although stem cells have been considered safe for avail-
able therapeutic strategies, there are still potential risks and
complications that may arise such as culture-induced senes-
cence, immune-mediated rejection, genetic instability, loss
of functional properties, and consequent malignant transfor-
mations. In this perspective, there is a prospect that stem
cell-EVs may overcome these limitations and therefore offer
novel and safe cell-free therapeutic opportunities. However,
their promise as real clinical applications still awaits further
investigations yet to be fully realized.
3. Extracellular Vesicles Mimic
Stemlike Phenotypes
Recent data from various different studies have shown stem
cell-EVs to traffic stem cell associated transcription factors
such as Nanog, Oct-4, HoxB4, and Rex-1 operating at the
level of pluripotent stem cells [37]. On top of that, they have
also been shown to express MSC markers such as CD105
[38], prominin-1/CD133 [39–41], and KIT [42]. More direct
effectors of the stem cell phenotype such as WNT [43, 44],
𝛽-catenin [45], and Hedgehog [46] have also been identified
on stem cell-EVs together with several other components
that may be considered potential factors in stem cell biology
(Table 1). Furthermore, ESC-EVs can be harvested from
exponentially growing ESCs, therefore suggesting that the
mechanism of EV release from ESCs is inherent [37].
Emerging evidence reveals that secreted vesicles from
stem cells could mimic a spectrum of stemlike phenotypes.
Ratajczak and coworkers provided the first evidence that EVs
released from stem cells might modulate the phenotype of
recipient cells [37]. In this study, they reported that EVs
released fromESCs sustained themaintenance of hematopoi-
etic stem/progenitor cell stemness andmultipotency by deliv-
ering specific proteins andmRNA, subsequently upregulating
the expression of early pluripotent and hematopoietic stem
cell genes [37]. A following study further confirmed this
by reporting that mRNA-carrying EVs from endothelial
progenitors induced a proangiogenic phenotype in quiescent
endothelial cells [47]. Moreover, it was recently revealed
that EV-mediated mRNA delivery into marrow cells could
introduce tissue-specific changes through the induction of
transcription in recipient cells [48], further indicating that
mRNAs present in stem cell-EVs are functional and have
regulatory effects.
Several studies have revealed that the key biological
features of stem cells, such as self-renewal, differentiation,
and maturation, could be mimicked by stem cell associ-
ated EVs [49–53]. Furthermore, stem cell-EVs have been
reported to coordinate physiological self-regenerative and
repair processes after tissue injury in a paracrine manner.
For instance, EVs released from MSCs (MSC-EVs) activate
repair processes by transferring miRNAs [54] and promoting
angiogenesis [55, 56], therefore suggesting EVs as functional
extensions of stem cells.
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Table 1: Stem cell signatures expressed and secreted in EVs.
Components Stem cell type/source Reference
Nanog, Oct-4, HoxB4
and Rex-1 ESCs [37]
CD105 CSCs, MSCs [38, 97]
Prominin-1/CD133 HPCs, melanocytes [39, 40]
KIT Mast/stem cells [42]
WNT Fibroblasts, DLBCL [43, 44, 96]
𝛽-catenin HEK [45]
Stem-cell antigen-1 MSCs [97]
TGF-𝛽1 Fibroblasts, epithelialcells [98]
TIA, TIAR, HuR, Stau1,
Stau2, RPS29, and Ago2 MSCs [54]
KGF MSCs [99]
Oct4 and Sox2mRNAs ESCs [62]
IGF-1R mRNA MSCs [100]
DEFA3, HBB, ITGA2B,
and ITGB3 mRNAs HPCs [101]
VEGF MSCs [68]
PDGFR-𝛽, TIMP 1 and
2, sphingomyelin, lactic
acid, and glutamic acid
MSCs [69]
CD34 MSCs [102]
E-cadherin MSCs [103]
Bcl-2 MSCs [104]
NEP MSCs [105]
ESCs: embryonic stem cells, CSCs: cancer stem cells, MSC: mesenchymal
stem cells, HPCs: haematopoietic precursor cells, DLBCL: diffuse large B-
cell lymphoma, HEK: human embryonic kidney cells, KIT: mast/stem cell
growth factor receptor, IGF-1R: growth factor receptor, TGF-𝛽1: transform-
ing growth factor beta 1, KGF: keratinocyte growth factor, ITGA; integrin
alpha, VEGF: vascular endothelial growth factor, PDGFR-𝛽: platelet-derived
growth factor receptor beta, TIMP: tissue inhibitor ofmetalloproteinase, and
NEP: neprilysin.
Interplay between stem cells and EVs reveals that EVs
could transmit multipotential traits and represent several
features of MSCs, such as multilineage differentiation, self-
renewal, and transcriptional regulation, therefore, inferring
their role as evolving factors in stem cell biology.
4. Stem Cell-EVs Contribute to
the Cell-Fate Determination
There is sufficient evidence to postulate that EVs carry
biological messages from parent cells that interact with
recipient cells and influence their normal physiology and
therefore their overall fate [33]. In the context of stem cell
biology, it is likely that the same principle applies (Figure 1),
as biological content from stem cell-EVs has been shown
to have the capability to influence and define cell fates of
future populations of resident cells, potentially producing
long lasting and stable transformation in genetic programs
[48, 57]. Furthermore, Quesenberry et al. have also proposed
that EV-mediated exchange of genetic information could be
an integral element of the continuum model of stem cell
biology, in which the differentiation decision of stem cells
is conditioned by the cell cycle transit and environmental
stimuli [58].
4.1. EV-Mediated miRNA Transport and Cell-Fate Determi-
nation. To sustain stemness, a set of transcriptional factors
are required to efficiently reprogram and self-renew the
pluripotency of recipient cells to enable them to differentiate
into various cell types [59]. Indeed, miRNAs are capable of
targeting and regulating the expression of stem cell associated
transcriptional networks by which they can induce pheno-
typic transition [60, 61]. In this context, EVs contribute to
such reprogramming and phenotypic switching by transfer-
ringmiRNAs as the delivery of selective sequesteredmiRNAs
in EVs to recipient cells has been reported [34].
For instance, EVs from bone marrow- (BM-) MSCs
shuttle the selected pattern of miRNAs to recipient cells
targeting genes involved in multiorgan development, cell
survival, and differentiation [54]. Furthermore, ESC-EVs
induce dedifferentiation and the expression of pluripotency
factors in their target cells by selective transfer of mRNA
and miRNA, which may initiate an early differentiation
process by targeting early transcriptional factors [62]. It has
also been reported that telocytes (TCs) secrete EVs loaded
with miRNAs that could modulate stem cell fates through
continuous posttranscriptional regulatory signals acting back
and forth between TCs and stem cells [63]. Moreover, Let-7
miRNA family expressed from human embryonic MSCs has
been shown to affect its downstream target hepatic nuclear
factor 4 alpha (HNF4A), indicating the possible role of
stem cells in differentiation processes through EV-mediated
transfer of miRNAs [64]. In addition, several other miRNAs
have been identified to potentially contribute to regulatory
mechanisms in stem cell biology (Table 2). These reports
therefore signify that stem cells may exhibit their biological
effects through EV-mediated shuttle of miRNAs for the
biological effects mediated by stem cells.
5. Stem Cell-EVs and Tumor Progression
The role of stem cells in tumor progression has been well
documented [65]; however, the mechanisms by which cancer
stem cell-derived EVs initiate and promote tumor progres-
sion are still uncertain. Recent evidence explains the interplay
between stemprogenitors and their secreted vesicles in tumor
progression. For example, it has been reported that EVs posi-
tive for the stem cell marker prominin-1 participate in Wnt
signaling and mediate prometastatic activity in melanoma
cells [40]. In addition, EVs from mast cells express and
shuttle KIT protein (mast/stem cell growth factor receptor),
which in turn promotes tumor growth in recipient lung
adenocarcinoma cells by activating the KIT-SCF signaling
pathway [42]. EVs from BM-MSCs have also been shown to
express higher levels of oncogenic proteins, cytokines, and
adhesion molecules that could be transferred to multiple
myeloma cells and modulate tumor growth in vivo [66].
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Figure 1: The role played by stem cell-derived EVs in the determination of cell fate. Stem cells use EVs to transfer miRNAs and stem cell
effectors in recipient cells, which target the regulatory networks and induce persistent genetic transformation and phenotypic switching of
resident cells towards cell-fate determination.
Table 2: Selectively enriched regulatory miRNAs from stem cell-
derived EVs.
miRNAs Stem celltype/source
Reference
miR-199b, miR-218, miR-148a,
miR-135b, and miR-221 MSCs
[106]
miR-223, miR-564, miR-451, and
miR-142-3p MSCs
[54]
miRNAs of 290 cluster ESCs [62]
let-7 miRNA family MSCs [64]
miR-133b MSCs [107]
miR-15a MSCs [66]
miR148a, miR532-5p, miR378,
and let-7f MSCs
[67]
miRNA-21, 34a MSCs [69]
miR-23b MSCs [73]
miR-16 MSCs [74]
miR-140 Preadipocytes [108]
miR-22 MSCs [109]
miR-221 MSCs [70, 110]
miR-210, miR-132, and
miR-146a-3p CPCs
[111]
miR-294 ESCs [112]
Recently, Eirin et al. reported that adipose MSC (AT-MSC)
derived EVs enriched with distinct mRNAs and miRNAs
regulate various physiological processes such as angiogen-
esis, adipogenesis, apoptosis, and proteolysis in recipient
cells [67]. Furthermore, EVs from BM-MSCs have been
reported to not only transport tumor regulatory miRNAs,
antiapoptotic proteins, and metabolites but also enhance the
expression of vascular endothelial growth factor (VEGF)
through the activation of extracellular signal-regulated kinase
1/2 (ERK1/2) pathway to promote growth of various tumors
[68, 69]. In addition, gastric cancer derived MSC-EVs have
been shown to deliver deregulated miRNAs to human gastric
cancer cells and promote their proliferation and migration
[70].
A subset of tumor-initiating cells expressing the MSC
marker CD105 in human renal cell carcinoma release EVs
that induce angiogenic phenotype in endothelial cells and
promote the formation of a premetastatic niche [38, 71]. Fur-
thermore, renal cell carcinoma-derived EVs induce persistent
phenotypical changes in MSCs accompanied with enhanced
expression of genes associated with cell migration, matrix
remodeling, angiogenesis, and tumor growth [71].
To the contrary, various reports also suggest the antitu-
morigenic effects of EVs from multiple stem cell types. For
instance, Bruno et al. have reported that BM-MSCs exert
inhibitory effects on tumor growth through the release of EVs
[72]. Furthermore, BM-MSC derived EV-mediated transfer
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of miRNAs from the bone marrow could promote dormancy
in metastatic breast cancer cells [73]. In addition, various
studies have reported the antiproliferative effects of MSC-
EVs through various mechanisms, for instance, miRNA-
mediated VEGF suppression in breast cancer cells [74] and
the downregulation of phosphorylation of Akt kinase in blad-
der tumor cells [75]. Similarly, a study by Fonsato et al. shows
that EV-mediated delivery of selected miRNAs from adult
human liver stem cells (HLSC) exhibits inhibitory effects on
hepatoma growth [76]. On the basis of this information and
on various other reports, MSC derived EVs could therefore
exert either anti- or protumorigenic effects depending on the
tumor type and stage of development [77].
Glioma-associated stem cells (GASCs) produce substan-
tial amounts of EVs that express and mediate glioma-stem
cell characteristics [78–80]. For instance, a recent study
reported that GASCs exhibit stem cell feature and anchorage-
independent growth and are capable of sustaining malig-
nant properties of both glioma cells and glioma-stem cells,
mainly through the release of EVs [78]. Furthermore, the
cargo (DNA, miRNA, transcripts, and proteins) from GASC
derived EVs may influence lineage specific dynamics of the
stem cell compartments [81].
MSC-EVs could also be engineered to play a poten-
tial role in cancer therapeutics as delivery vehicles. For
instance, Munoz et al. successfully reported the delivery of
functional anti-miR-9 to glioblastoma (GBM) cells through
MSC-EVs, therefore increasing their level of chemosensitivity
substantially [79]. In addition, EV-dependent phenotypes of
stem cells such as neurosphere growth and endothelial tube
formation were attenuated by loading miR-1 into GBM-EVs
that were exposed to the glioblastoma microhabitat [80].
Furthermore, a recent study by Katakowski et al. observed
that intratumor injection of miR-146 expressing MSC-EVs
significantly inhibited glioma xenograft growth [82]. Like-
wise, Pascucci et al. also reported the potential ability of
MSCs to package/incorporate and deliver active drugs such
as paclitaxel through EVs to inhibit tumor progression [83].
These studies therefore indicate the potential capability and
utility of stem cell-EVs as drug delivery mechanisms for
cancer therapy.
5.1. Ways by Which Stem Cell-EVs Influence the Tumor
Microenvironment. The principle properties of cancer stem
cells (CSCs) are maintained by niches which are anatomically
distinct regions within the tumor microenvironment [84].
The premetastatic niche plays a role in dormancy, relapse,
and the development of metastasis. It has been hypothesized
that EVs from CSCs may behave as metastasomes, helping
the implementation of secondary lesions by transmission
of the metastatic phenotype via EV-borne tumor RNA
signatures to the target organ [85]. Since the construction
of a premetastatic niche is an essential early step required
for initiated cells to survive and evolve [86], it could be
speculated that stem cells may contribute to the construction
of premetastatic niches, at least in part, by secreting EVs.
This could be supported through the observation ofGrange et
al., whereby interactions between endothelial cells and CSCs
induced phenotypical changes in MSCs and promoted the
formation of lung premetastatic niches through the release of
EVs [38].
5.1.1. Fibroblastic Differentiation and Stroma. Tumor cells
have the ability to efficiently “educate” MSCs to induce
changes in the local microenvironment through the release
of EVs. For instance, tumor cell-derived EVs have been
observed to propagate the construction of the tumor stroma
through fibroblastic differentiation of MSCs [87]. Similarly,
EVs from ovarian cancer cells have also been reported to
induce adipose stromal cells (ASCs) to acquire the charac-
teristics of tumor-supporting myofibroblasts [88]. A similar
phenotypic switch was also noted in prostate cancer (PC)
EVs whereby they influenced the differentiation of MSCs
into proangiogenic and proinvasive myofibroblasts that was
associated with disease promotion [89]. In another study,
EVs from PC cells induced phenotypic transformation in PC
patient ASCs to form prostate-like neoplastic lesions [90].
On top of that, tumor derived EVs can initiate phenotypic
differentiation of MSCs into cancer-associated fibroblasts
(CAFs) through signaling pathways [91]. These activated
CAFs influence tumor progression through the secretion
of metalloproteinases-rich EVs that promote cell motility
and activate RhoA and Notch signaling in cancer cells [92].
Moreover, these EVs also play a role in chemoresistance and
tumor relapse by promoting clonogenicity and growth of
CSCs which are inherently resistant to cell death [93].
5.1.2. Crosstalk among Stromal Elements. EV-mediated dyn-
amic crosstalk within the stroma could relocalize the onco-
genic factors that can generate a tumor-initiating niche.
This can be speculated from the fact that carcinogenesis
involves the relocalization of CAFs to the tumor site therefore
sustainingmetastasis [94].The general involvement of EVs in
intercellular communication suggests that theymay also have
a role in information exchange within stem cell hierarchies,
whereby cancer stemlike cells may transmit signals to their
stroma via EVs. Undeniably, it is well known that ESC-EVs
transfer mRNAs, miRNAs, and proteins to recipient cells and
therefore are important mediators of crosstalk within stem
cell niches [95].
Stromal cell-derived EVs can interact with cancer cells
and exchange oncogenic signatures present in tumor-
associated stroma. For example, intercellular communication
mediated by fibroblast-secreted EVs promotes cancer cell
motility via autocrineWnt-planar cell polarity signaling path-
way to drive invasive activities [43]. Furthermore, the Wnt3a
has been shown to be exported via EVs to neighboring cells
which in turn modulates the population equilibrium in the
tumor towards progression [96]. Such features are expected
to be established very early during tumorigenesis; however,
the prolonged intercellular communication could eventually
be sustained and ultimately aggravate tumor growth. It
could also be anticipated that the tumor microenvironment
may host nontumorigenic multipotent stem cells that could
likewise support the biological activity of tumor-initiating
cells through the release of EVs.
Stem Cells International 7
5.1.3. Endothelial Cell Growth and Angiogenesis. Angiogen-
esis is one of the underlying hallmarks of a developing
tumor microenvironment. It is activated by proangiogenic
factors such as VEGF thereby promoting tumor growth,
invasion, and metastases. In response to hypoxia (a hallmark
of developing tumors), MSCs increase EV production, which
in turn promotes angiogenesis [113] and endothelial cell
growth in vitro [114]. This proangiogenic property of stem
cell-secreted EVs is reported to be linked with the activa-
tion of the ERK signaling pathway therefore increasing the
expression of VEGF in tumor cells [68]. Furthermore, AT-
MSC derived EVs have also been implicated to influence AT-
MSC induced angiogenesis. Interestingly, the platelet-derived
growth factor (PDGF) was identified to elicit this effect
by stimulating AT-MSCs to release EVs with an enhanced
proangiogenic potential [115]. In addition, AT-MSC derived
EVs have been shown to interact with endothelial cells
as well, thereby stimulating proangiogenic activity in the
tumor microenvironment, possibly through the exchange of
angiogenic growth factors [116].
EV-assisted targeting of key regulatory signaling path-
ways in the tumor microenvironment such as Wnt, Hedge-
hog, and angiogenic pathways (i.e., VEGF) could inhibit
tumor growth. A recent study by Gernapudi et al. showed
that a critical signaling axis, miR-140/SOX2/SOX9, which
regulates differentiation, stemness, and migration in the
tumor microenvironment, could be targeted to obstruct
tumor progression [108]. Likewise, EV-assisted targeting of
the VEGF pathway in the tumor microenvironment could
exert antiangiogenic effects and inhibit tumor growth [74].
However, monitoring a complex stromal network in a
dynamic tumormicroenvironment has been and still remains
technically challenging.
In summary, EVs secreted from cancer cells educate
MSCs to undergo neoplastic transformation into tumor-
associated fibroblasts in local stroma. In addition, EV-
mediated dynamic interactions amongst stromal elements
and the concomitant recruitment of oncogenic CAFs, growth
factors, immune molecules, and several other related mech-
anisms shape a tumor niche capable of development and
growth (Figure 2).
6. Stem Cell-EVs: Emerging Factors in
Immunomodulation and Immunotherapy
There is increasing evidence implicating EVs to play a
critical role in immune regulatory mechanisms compris-
ing of both immunoactive and suppressive activities [117–
119]. Conversely, studies elucidating the role of EVs from
immunologically active stem cells are seldom reported in the
scientific literature, possibly because their role as potential
factors in immunomodulation is still novel. MSCs have been
shown to secrete immunologically active EVs, which induce
higher expression of anti-inflammatory transcripts such as
interleukin 10 (IL10) and transforming growth factor𝛽1 (TGF
𝛽1) and attenuated levels of proinflammatory transcripts such
as IL1B, IL6, tumor necrosis factor 𝛼 (TNF𝛼), and IL12P40
[120]. Furthermore, infusion of MSC-EVs significantly
enhanced the survival and delayed the rejection of allogenic
skin graft inmice with a corresponding increase in regulatory
T cells (Tregs) therefore indicating some role of EVs in
immunomodulation [120].
Islet derived MSCs have been reported to release
immunostimulatory EVs that could activate autoreactive B
and T cells in nonobese diabetic (NOD) mice. Furthermore,
immunization with EVs also promotes the expansion of
transferred diabetogenic T cells and accelerates the effector
T cell-mediated destruction of islets suggesting that stem
cell-EVs act as autoantigen carriers with the potential to
trigger autoimmune responses [97]. On the other hand,
human adipose MSC derived EVs have been reported to
exert inhibitory effects on the differentiation and activation
of T cells followed by reduced T cell proliferation and IFN-𝛾
release, therefore suggesting MSC-EVs to play a potential
therapeutic role in the treatment of inflammation-related
diseases [121]. Furthermore, EVs from immune cells can also
have an effect on MSC cells. For instance, Ekstro¨m et al.
showed that monocyte-derived EVs can induce increased
gene expression of osteogenic markers in human MSCs,
indicating that monocyte-derived EVs play a role in bone
healing [122].
EVs from acute myeloid leukemia- (AML-) blasts that
are positive for the hematopoietic progenitor cell antigen
CD34 have been reported to be biologically active. Upon
coincubation with natural killer (NK) cells, these AML-
blast EVs efficiently downregulated the expression of surface
NKG2D (an activator of NK cells) indicating a possible
function in mediating immunosuppression in AML [123].
In addition, immunocaptured blast-derived EVs could also
serve as biomarkers for AML during the course of therapy as
a measure of disease progression or response to therapy.
Using a model of human-into-mouse xenogeneic graft-
versus-host disease (x-GVHD), BMSCs were shown to play
a role in immunomodulation, mediated by human CD4+
Th1 cells [124]. Notably, recipients treated with BMSCs
had elevated levels of exosomes expressing CD73 in the
serum that promoted the accumulation of adenosine ex vivo.
Furthermore, on inhibiting the adenosine A2A receptor,
the immunomodulatory property of BMSCs was abrogated,
therefore implying a possible role of BMSC-EVs in an
adenosine based immunosuppressive mechanism mediated
in a paracrine fashion [124]. Recently, MSC-EVs were tested
in a human patient to treat GVHD, whereby they were
shown to be well tolerated [125]. Interestingly, the EV based
treatment resulted in a reduced proinflammatory cytokine
response to the patient’s peripheral blood mononucleated
cells (PBMCs) in vitro and the clinical GVHD symptoms
improved significantly shortly after the start of the EV therapy
[125].
Although initial findings ascertain that EVs could be a
promising therapeutic source for the treatment of immune-
inflammatory diseases [126, 127], translating this technology
into EV-mediated stem cell therapy to achieve promising
outcomes with minimized toxic effects and safety risks still
needs to be explored.
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Figure 2: Contribution of stem cell-derived EVs in the construction of the tumor microenvironment. Stem cell-derived EVs influence the
presence of cancer-associated fibroblasts (CAFs), inflammatory immune cells, metalloproteinases, angiogenic growth factors, and regulatory
RNAs, which shape the tumor microenvironment. Extracellular matrix (ECM) remodeling, endothelial cell growth, cell migration, and
angiogenesis generate a permissive tumor niche.
7. Stem Cell-EVs and Tissue Repair
The therapeutic applications of stem cells for the treatment
of various injuries and diseases have received considerable
attention in recent years. However, investigations into the
possibility of utilizing stem cell-EVs in regenerativemedicine
are still in their early stages. Recently, it has come to light that
stem cells, particularly MSCs, use EVs for tissue repair and
regeneration through the transfer of transcription factors,
anti-inflammatory factors, and growth factors to target cells
in a paracrine fashion. In this section, we discuss the regen-
erative abilities of MSC-EVs to recover vascular functions,
repair injuries, and restore tissue homeostasis.
7.1. Stem Cell-EVs: Allies in the Fight against Cardiovascu-
lar Diseases. Stem cells have been suggested as an ideal
novel therapeutic approach against cardiovascular diseases.
However, an important feature of this approach is that EVs
subsequently released from stem cells are a newly discovered
source of cardiovascular protection. Improved heart function
and vessel formation have been attributed to EVs released
from stem cells, largely due to their anti-inflammatory
and antiapoptotic effects (discussed below). Moreover, their
effects can equally be extended towards neovascularization
and cardiac regeneration.
Stem cell-EVs participate in the suppression of inflam-
matory responses in order to enhance cardiac functions.
For instance, MSC-EVs mediate cytoprotective actions in
a model of pulmonary hypertension by suppressing hyper-
proliferative pathways such as the signal transducer and
activator of transcription 3 (STAT3) pathway as well as
upregulating miRNAs that are downregulated during pul-
monary hypertension [128]. Moreover, MSC-EVs moderate
inflammatory reactions and rapidly ameliorate myocardial
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functions during ischemia/reperfusion injury, possibly by
restoring bioenergetics, activating PI3K/Akt pathway, and
triggering prosurvival signaling [129].
Cardiomyocyte progenitor cells (CPCs) have been shown
to stimulate the migration of endothelial cells as well as pro-
moting neovascularization that can potentially improve heart
function [130]. Recently, EVs secreted by human CPCs have
also been implicated with similar cardioenhancing functions
mainly through inhibiting apoptosis, promoting tube forma-
tion, and initiating angiogenesis in cardiomyocytic cells [111].
Furthermore, MSC derived EVs also protect cardiac tissue
from ischemic injury primarily by enhancing angiogenesis,
blood flow recovery, and reducing infarct size [131]. After
myocardial infarctions, they are linked with promoting
recovery of cardiac functions via the Akt signaling pathway
[132].
Ischemic preconditioning can potentiate the protective
effects of MSCs during ischemic cardiomyocytes (CMs)
injury. This is mainly achieved through the secretion of
EVs that deliver miRNAs with antiapoptotic effects [109].
Furthermore, EVs released by the heart after ischemic
preconditioning also contribute towards cardioprotection
[133]. Interestingly, heat shock proteins have been shown
to improve stem cell survival in an ischemic environment.
This therefore promotes a prosurvival phenotype in CMs
through heat shock factor-1 (HSF-1) and miR-34a interaction
that is found to be mediated by EVs [134]. Other than
proteins, MSCs are also capable of transferring antiapoptotic
miRNAs to CMs via EVs that transcriptionally repress the
expression of apoptotic genes, activate cell survival signaling
pathway, and ensure cardioprotection [110, 135]. Such delivery
of miRNAs could potentiate antiapoptotic effect of MSCs by
inhibiting PUMA (p53-upregulated modulator of apoptosis)
to promote cardiomyocyte survival [110].
Injured epithelial cells produce TGF-𝛽1-containing EVs
with defined genetic information able to activate fibroblasts,
which initiate tissue regenerative responses and fibrosis
[98]. Cardiac fibrosis is antagonized by stem cell-secreted
EVs, exhibiting a substantial protection against myocardial
infarction [109]. Furthermore, MSC-EVs have a replacement
or cytoprotective effect, thus demonstrating potential ther-
apeutic use in stem cell transplantation for the treatment
of pulmonary fibrosis [136]. Notably, ESC-derived EVs can
also effectively augment cardiac function in infarcted hearts
through enhanced neovascularization, cardiomyocyte sur-
vival, and reduced fibrosis after infarction. The underlying
basis for this beneficial effect was linked to the delivery of ESC
specific miR-294 to CPCs promoting increased survival, cell
cycle progression, and proliferation [112]. In addition, CD34+
stem cell-EVs also mediate the transfer of angiogenic factors
to the surrounding cells, whichmay be beneficial in achieving
functional recovery after ischemic injury [102]. Therefore,
stem cell-EVs from various different tissue locations with
their above mentioned healing properties have the potential
to act as significant therapeutic agents in the fight against
cardiovascular diseases.
7.1.1. Protective and Therapeutic Role against Kidney Injury.
MSCs have been implicated in protecting against renal
damage through their paracrine effects. By use of a genetic
fate-mapping technique, it has been shown that the recovery
from acute kidney injury (AKI) depends on the intrinsic
regenerative ability of tubular epithelial cells that undergo
mesenchymal dedifferentiation and reentry into cell cycle
[137]. Experiments performed by Bi et al. show that MSC
conditioned medium has the ability to mimic the effects of
MSC cells therefore indicating a paracrine form of action
[138].
Recent evidence has also demonstrated that MSC-EVs
could confer the paracrine actions of their parent cells and
therefore contribute towards renal protection as well. For
instance, Bruno et al. observed that humanMSC-EVs induce
recovery in a murine model of AKI in a manner comparable
to that of the cell of origin [139]. Furthermore, evidence of
mRNAs carried by EVs being translated into proteins has
also come to light in both in vitro and in vivo conditions
[139]. For example, Tomasoni et al. reported that MSC-EVs
mediated the transfer of human IGF-1R mRNA to murine
proximal tubular cells, which was subsequently followed by
the enhancement of cell sensitivity to the regenerative actions
of IGF-1 [100]. EVs from human umbilical cord-derived
MSCs (hUC-MSCs) have also been demonstrated to trigger
the ERK 1/2 pathway thereby inducing proliferation of tubular
cells and protection against cisplatin-induced apoptosis [140].
EVs from human adult MSCs exhibit protective proper-
ties against AKI, largely by inhibiting apoptosis and stimu-
lating proliferation of tubular epithelial cells [141]. This was
further confirmed by Bruno et al., who showed, in a cisplatin-
induced lethal model of AKI, that MSC-EVs enhanced the
survival of mice through the upregulation of antiapoptotic
genes and downregulation of proapoptotic genes [142]. This
increased expression was attributed partly to EV-mediated
miRNA transfer and in part due to the EV-triggered miRNA
transcription [143]. Moreover, miRNA-depleted EVs released
by Drosha knockdown MSCs failed to protect the kidney
from acute injury [144], indicating that miRNA content of
EVs is essential for their biological activity.
Using a mouse remnant kidney model, it was shown that
BMSC-EVs could have protective effects against renal injury
[145]. Furthermore, endothelial progenitor cell-derived EVs
exert a protective effect against mesangial cell injury during
Thy1.1 glomerulonephritis [146], andHLSC-derived EVs have
the potential to influence renal function and morphology, in
a manner comparable to the cells of origin [147]. Administra-
tion of MSC-EVs might also remarkably protect mice against
renal failure, probably by transferring selective patterns of
miRNAs fromMSC-EVs to target cells and protection against
EMT for restoration [148]. Hence, these studies concur on the
therapeutic ability of stem cell-EVs and their potential to be
applied as treatment for renal diseases in the future.
7.1.2. Recovering Lung and Liver Injuries. EVs from lung cells
have been shown to induce the expression of mRNAs coding
for lung specific proteins such as Clara cell protein and
aquaporin-5 and A-D surfactants in bone marrow cells [149].
Furthermore, this phenomenon is enhanced significantly
during lung injury [149].
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Acute and chronic lung injuries could in theory be recov-
ered through the paracrine actions ofMSC-EVswhich confer
a stem cell-like phenotype in injured cells for the activa-
tion of self-regenerative programs [99]. Moreover, ischemic
preconditioning can also potentiate the protective effects of
MSCs against endotoxin-induced acute lung injury through
the secretion of EVs [150].
HLSC-EVs may also have a role in accelerating the
morphological and functional recovery of injured cells during
liver damage, mainly through horizontal transfer of specific
mRNA subsets to recipient cells [151]. Recently, it has been
reported that transplantation of EVs released from hUC-
MSCs could reduce the surface fibrous capsules, soften
their textures, and alleviate hepatic inflammation in fibrotic
liver [103]. Moreover, it was observed that human liver
cells undergo typical EMT after induction with recombinant
human TGF-𝛽1, whereas MSC-EV treatment reverses the
expression of EMT-associated markers [103], indicating that
MSC-EVs could prevent liver fibrosis and ameliorate hep-
atocyte protection through EMT inhibition. Furthermore,
MSC-EVs appear to promote hepatic regeneration following
drug-induced liver injury, mainly through the activation of
proliferative and regenerative responses [152]. This therefore
demonstrates the ability of EVs to act as functional messen-
gers of stem cells.
7.1.3. Stem Cell-EVs and Neuroprotection. There are several
studies that have recently come to light that associate MSC-
EVs with a neuroprotective role along with stem cells.
For instance, EV-mediated transfer of miRNAs from MSCs
promotes neural plasticity and functional recovery of neu-
rons and astrocytes after treatment for stroke in rats [107].
Furthermore, EV-mediated delivery ofmiRNAs enhances the
expression of glutamate transporters, suggesting an efficient
route of therapeutic miRNA delivery to the brain. A recent
study by Raisi et al. reported that EVs produced from anti-
inflammatory MSCs enhanced sciatic nerve regeneration
in rats which could be potentially applied in peripheral
nerve cell therapy [153]. In addition, EVs from embryonic
cerebrospinal fluid have been reported to carry evolutionarily
conserved proteins andmiRNAs, which promote neural stem
cell proliferation [154].
Theprotective effects ofMSC-EVswere recently observed
against glutamate-induced excitotoxicity in rat pheochromo-
cytoma via a PI3K/Akt dependent pathway [104]. Investiga-
tion of a possible underlying mechanism for this protection
revealed that MSC-EVs were responsible for downregulating
Bax expression accompanied by reduced cleavage of caspase-
3, upregulation of Bcl-2 expression, and Akt phosphorylation
in glutamate-treated cells, therefore providing a prosurvival
fate for affected cells [104]. Transplantation of MSC-EVs
could therefore be a potential strategy to treat neuronal
diseases involving excitotoxicity.
MSC-EVs may also have effects on neurovascular plas-
ticity during traumatic brain injury by inducing endoge-
nous angiogenesis and neurogenesis and reducing neuronal
inflammation [155, 156]. Furthermore, a study by Katsuda et
al. has reported the role of human AT-MSCs derived EVs as
a novel therapeutic approach for Alzheimer’s disease (AD)
as they were found to be loaded with enzymatically active
neprilysin (NEP) that potentially contributes to amyloid-
𝛽 clearance in the brain [105]. These observations and
others therefore support the potential of stem cell-EVs as
a means of cell-free therapy against cerebral injuries and
neurological diseases.
In summary, stem cells induce regenerative programs
in injured tissues of different organs through EV-mediated
transfer of anti-inflammatory miRNAs and growth factors.
These, in turn, ameliorate the damage (Figure 3) by activating
different signaling pathways, which have an antiapoptotic
and angiogenic effect therefore significantly restoring the
bioenergetics, improving blood flow recovery, and inducing
stemlike phenotypes in injured organs.
The ability of EVs to mediate bidirectional intercellular
communication suggests that they could not only send infor-
mation from stem cells to injured cells but also communicate
from injured cells back to stem cells. In this regard, the
future clinical contributions of EVs could therefore be (1)
translocation of regenerative signatures at injured sites to
trigger repair process, (2) transmission of signals related to
tissue injury towards stem cells, to generate more progeny for
maintaining stem cell equilibrium and continuous supplies to
injured sites, and (3) EVs from injured tissues that could also
stimulate stem cells to acquire features of the injured cells.
8. Concluding Remarks and Future Perspective
Stem cell-EVs provide a new interpretation of stem cell
plasticity that is still a hotly debated topic [157]. EV-mediated
bidirectional exchange of information between progenitor
cells and tissue differentiated cells leads to phenotypic
changes that provide evidence of previously uncertain cell
plasticity. This could be beneficial to clinical implications of
EVs for future regenerative medicine.
Elucidating the contribution of stem cell-EVs in
premetastatic niche formation and biological characteristics
of the cancerous stromal elements may offer novel
targeting opportunities and have prognostic and predictive
values. However, monitoring the target complex tumor
microenvironment remains a technical challenge.
Moreover, the immunomodulatory features of MSC-EVs
could be extended in the treatment of immune diseases,
reducing potential safety risks originated from conventional
immunotherapy such as susceptibility to infection, immune
dysfunction, autoimmune responses, and/or increased risk of
developing cancer. Conceivably, EVs from immunoreactive
MSCs could be novel therapeutic tools against inflammation-
associated diseases [125].
Despite the improvements of surgical procedures in
organ transplantation and cell-based therapies in the last
decade, current methods present potential complications
(i.e., toxicity and organ rejection), which remains dismal for
improving long-term survival and reducing mortality. It is
therefore necessary to look for alternative and more reliable
procedures, which could potentiallyminimize associated risk
factors. In this regard, EV based cell-free therapy could be
a preferred option as it would improve patients’ outcome
considerably, by reducing the complications associated with
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Figure 3: Schematic representation of the regenerative effects of stem cell-derived EVs. MSCs use EVs to ameliorate tissue damage through
translocating growth factors, anti-inflammatory, antiapoptotic, and proangiogenicmolecules, to sites of injury where they induce and regulate
regenerative phenotypes.
cell-based treatments. For instance, ESC-EVs provide a novel
cell-free system that uses the immense regenerative power of
ES cells while avoiding the risks associated with direct ES or
ES-derived cell transplantation and risk of teratomas [112].
Furthermore, EVs have the ability to extend the therapeutic
effects and functions of stem cells in both a local and systemic
environment. Hence, the administration of stem cell-derived
EVs would reduce potential safety risks associated with
cellular therapy and/or transplantation surgery.
However, further studies are needed to define whether
EVs permanently or transiently change the “genetic finger-
print” of an injured target organ and the consequences of it.
Preliminary studies on acute kidney injury indicate a restora-
tion of a persistently normal renal molecular pattern after EV
treatment [144]. However, the effect may be dose dependent
and increasing doses of EVs may produce unwanted effects
as we observed in preliminary experiments with adipose-
derived MSCs.
As MSCs have the potential to differentiate into
other types of viable replicating cells, replacing their
transplantation with administration of MSC-EVs (which
mimic similar functions as MSCs) would reduce this
possibility and maintain the therapeutic benefits at the same
time. However, the mobilization of EVs and homing to
specific tissues are still a major concern. Given that EVs
express specific membrane receptors and proteins specific
to certain cell types [158], it may be possible to identify a
potential mechanism to direct EVs as well as stem cells to a
particular tissue. Receptor-ligand mediated interactions and
homing could also facilitate the cellular uptake of EVs and
their associated cargo by recipient injured cells. Furthermore,
as a reparatory response, the mobilization of EVs to injured
zones could be a result of dynamic interactions among
stromal elements. It is quite possible that, in response to
an injury or transplant, the enhanced release of EVs could
create a gradient that may educate them to mobilize to the
site of injury.
Since EVs aremore suitable formonitoredmanufacturing
processes, they could be engineered to express and deliver
regenerative signatures to target sites. However, a potential
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challenge is the lack of standardization of the existing tech-
nologies to isolate and characterize EVs for their effective
therapeutic utility. Therefore, a combination of different
high throughput methods could overcome the potential
limitations related to EV detection and characterization [5].
Particularly, the technologies for the isolation and character-
ization of stem cell-EVs must be improved and optimized
[159], ensuring the purity of EVs that is critical for developing
cell-free therapeutic strategies using stem cell-EVs in the
future.
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